Evidence map›Paper›PMID 41029933›Full record

ReviewCurrent pharmaceutical design2026

Para-probiotics as Novel Anti-Inflammatory Agents: Insight into Health Benefits and Therapeutic Applications.

Sumel Ashique, Biplab Debnath, Anas Islam, Mohd Tariq, Tahreen Taj, Shubhrajit Mantry, Sathvik Belagodu Sridhar, Bharti Verma, Nitish Kumar, Krishnendu Adhikary and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Preventive Effects of Probiotic and PostbioticJournal of microbiology and biotechnology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sumel AshiqueDepartment of Pharmaceutical Technology, Bharat Technology, Uluberia, 711316, West Bengal, India.ORCID 0000-0003-4362-2830
Biplab DebnathDepartment of Pharmaceutical Technology, Bharat Technology, Uluberia, 711316, West Bengal, India.
Anas IslamDepartment of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, 226026, India.
Mohd TariqDepartment of Biotechnology, Graphic Era (Deemed to be University), Dehradun, Uttarakhand, 248002, India.
Tahreen TajDepartment of Pharmacology, Yenepoya Pharmacy College and Research Centre, Yenepoya (Deemed to be) University, Mangalore, Karnataka, 575018, India.
Shubhrajit MantryDepartment of Pharmacy, Sarala Birla University, Mahilong, Purulia Road, Ranchi, 835103, Jharkhand, India.
Sathvik Belagodu SridharRAK College of Pharmacy, RAK Medical & Health Sciences University, Ras al Khaimah, UAE.
Bharti VermaSRM Modinagar College of Pharmacy, SRM Institute of Science and Technology (Deemed to be University), Delhi-NCR Campus, Modinagar, Ghaziabad, Uttar Pradesh, 201204, India.
Nitish KumarSRM Modinagar College of Pharmacy, SRM Institute of Science and Technology (Deemed to be University), Delhi-NCR Campus, Modinagar, Ghaziabad, Uttar Pradesh, 201204, India.
Krishnendu AdhikaryDepartment of Medical Lab Technology, Paramedical College Durgapur, Helen Keller Sarani, Durgapur, West Bengal, 713212, India.
Dipali SaxenaDepartment of Food Nutrition, Shri Vaishnav Institute of Home Science, Shri Vaishnav Vidyapeeth Vishwavidyalaya, Indore, Madhya Pradesh, 453111, India.
Mudasir MaqboolDepartment of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar, 190006, Jammu and Kashmir, India.ORCID 0000-0002-9036-008X
Md Sadique HussainUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, 248007, India.ORCID 0000-0002-3554-1750

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Para-probiotics, also referred to as non-viable microbial cells or cell components that confer health benefits, are emerging as promising agents in the prevention and management of inflammation-associated diseases. Unlike traditional probiotics, which require viability for efficacy, these inactivated forms offer significant advantages in terms of safety, stability, and applicability in vulnerable populations, including immunocompromised individuals. Recent studies have highlighted their capacity to modulate immune responses, enhance mucosal defense mechanisms, and reinforce intestinal barrier integrity through interactions involving microbial-associated molecular patterns (MAMPs) and host pattern recognition receptors. Such interactions influence signaling cascades like NF-κB, MAPKs, and inflammasome pathways, contributing to antiinflammatory and immunomodulatory effects. One of the key advantages is the reduced risk of adverse effects and concerns associated with live probiotic use. In addition, their robust physicochemical stability under industrial processing conditions supports their incorporation into a range of functional foods and nutraceuticals. Despite these advantages, their mechanisms of action remain incompletely understood and require further investigation. This review synthesizes current evidence on their anti-inflammatory properties, highlights preclinical and clinical studies, and discusses technological approaches for their production. Overall, these bioactives represent a safe, stable, and efficacious alternative to traditional probiotics in managing inflammatory disorders.

Indexed as

Anti-Inflammatory AgentsInflammationProbioticsAnimalsHumansAnti-Inflammatory Agentsfunctional foodsgut microbiotaimmune modulationinflammationnon-viable probioticsPara-biotics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.